top of page
DEMETHER
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (mBC) PATIENTS
CLINICAL TRIAL DETAILS
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER PATIENTS (DEMETHER).
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast Cancer
165
II
EU
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
----
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page